ProQR Remains Confident In Pipeline After Sepofarsen Flop, Analysts Not So Much
Executive Summary
The company is pinning hopes on its Usher syndrome and retinitis pigmentosa programs, but the disconnect between Phase I/II success and Phase II/III failure dented analysts’ enthusiasm.